BOVIET SOLAR TO SHOWCASE NEW TOP-PERFORMING PV MODULES AT ACP CLEAN POWER TRADE SHOW AND CONFERENCE
SAN JOSÉ, Calif., May 6, 2025 /PRNewswire/ -- Boviet Solar Technology Co. Ltd. (the 'Company' or 'Boviet Solar'), a leading solar energy technology company specializing in monocrystalline PV cells and Gamma Series™ Monofacial and Vega Series™ Bifacial PV modules, will be showcasing its new lines of N-Type solar cell-based PV modules at the ACP Clean Power exhibition and conference from May 19 to 22, 2025 in Phoenix, Arizona. Boviet Solar will be exhibiting in the North Building-Lower Level of the Phoenix Convention Center at booth number 2037.
Boviet Solar's Gamma Series™ Monofacial and Vega Series™ Bifacial PV modules are crafted with advanced technology and built from durable components under strict quality control and high-tech manufacturing processes. Featuring N-Type cell, half-cut, multi-busbar, and large cell designs, these modules deliver higher power output, capture more light, and generate more energy. This ensures exceptional power, performance, and reliability for residential, commercial, industrial, and utility-scale solar solutions, giving developers, installers, and EPCs the confidence and peace of mind they need for their investments.
The company will display the latest module offerings:
Vega Series™ Mono-Monofacial PV Module I N-Type Application Type: Residential Maximum Power Output: 435W Design Type: Black Frame / Transparent Back Module Efficiency: 22.28% Cell Efficiency: 24.5% Module Dimensions: 67.8 x 44.65 x 1.19 inches Module Weight: 44.09 lb Module Code: BVM7609M-XXX-H-HC-BF
Vega Series™ Mono-Bifacial PV Module I N-Type
Application Type: C&I / Utility
Maximum Power Output: 580W
Design Type: Single Glass / Silver Frame / Transparent Backsheet
Module Efficiency: 22.45%
Cell Efficiency: 24.5%
Module Dimensions: 89.69 x 44.65 x 1.38 inches
Module Weight: 61.73 lb
Module Code: BVM7612M-XXX-H-HC-BF
Vega Series™ Mono-Bifacial PV Module I N-Type
Application Type: Utility
Maximum Power Output: 630W
Design Type: Double Glass / Silver Frame
Module Efficiency: 23.3%
Cell Efficiency: 24.5%
Module Dimensions: 93.86 x 44.65 x 1.3 inches
Module Weight: 71.65 lb
Module Code: BVM8611M-XXXR-H-HC-BF-DG
Vega Series™ Mono-Bifacial PV Module I N-Type
Application Type: Utility
Maximum Power Output: 720W
Design Type: Double Glass / Silver Frame
Module Efficiency: 23.18%
Cell Efficiency: 24.5%
Module Dimensions: 93.86 x 51.30 x 1.3 inches
Module Weight: 83.78 lb
Module Code: BVM8611M-XXX-H-HC-BF-DG
'We're looking forward to connecting with our partners and clients at ACP Clean Power, where we'll share exciting developments happening at our company, including Boviet's U.S. PV Module Factory which started Phase 1 production on April 24th 2025 and its upcoming completion of Phase 2 PV cell manufacturing, as well as advancements in our manufacturing, technology, and product innovations,' said Sienna Cen, President of Boviet Solar USA. 'It's going to be a fantastic event for Boviet Solar.'
With a proven track record of successfully working with many of the industry's leading players, Boviet Solar has been named a BNEF Tier 1 PV module manufacturer, a Wood Mackenzie top 10 global bankable PV module manufacturer, and a Sinovoltaics top 10 global financially stable PV module manufacturer. Boviet Solar's PV modules are known for their power, performance, and quality and have been rated as top performers on PVEL Kiwa's PV Module Reliability Scorecard since 2019.
About Boviet Solar
Boviet Solar is a leading solar technology company founded in 2013 in Vietnam, specializing in the manufacturing of high-performance Monocrystalline PV cells and high-quality Gamma Series™ Monofacial and Vega Series™ Bifacial PV modules for residential, commercial, industrial, community and utility-scale solar applications. Boviet Solar combines business acumen, financial stability, technological expertise, and manufacturing excellence to produce top-performing PV modules, while fostering mutual partnerships, ensuring sustainability, supply chain traceability, and compliance with international trade standards.
Boviet Solar has earned a reputation for excellence, holding a Bloomberg New Energy Finance (BNEF) Tier 1 ranking, being recognized as one of the top 10 most reliable PV module manufacturers by Wood Mackenzie and Sinovoltaics, and consistently rated as a Top Performer in Kiwa PVEL's PV Module Reliability Scorecard.
Boviet Solar's global headquarters is in Vietnam, with manufacturing facilities in both the USA and Vietnam, featuring an annual PV cell and PV module capacity of 3.0 GW, along with additional operations in the USA, Germany, and other regional markets. For more information about our company and products, please visit www.bovietsolar.com
MEDIA INQUIRES:
Songül Atacan
Head of Global Brand and Marketing
Boviet Solar
[email protected]
View original content: https://www.prnewswire.com/news-releases/boviet-solar-to-showcase-new-top-performing-pv-modules-at-acp-clean-power-trade-show-and-conference-302442452.html
SOURCE Boviet Solar USA
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
42 minutes ago
- Yahoo
Cancer Pain Market Set to Transform by 2034 Due to Launch of Breakthrough Therapies
According to DelveInsight's analysis, the growth of the cancer pain market is expected to be mainly driven by increasing incidence and advances in disease mechanisms have yielded new diagnostic and therapeutic approaches, opening the way to more drug development. The market is expected to show positive growth, mainly attributed to the increasing cases and also, the launch of upcoming therapies during the forecast period. LAS VEGAS, June 12, 2025 /PRNewswire/ -- DelveInsight's Cancer Pain Market Insights report includes a comprehensive understanding of current treatment practices, cancer pain emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan]. Key Takeaways from the Cancer Pain Market Report According to DelveInsight's analysis, the market size for cancer pain is expected to rise at a significant CAGR by 2034. The United States is expected to account for the highest market size of cancer pain, of the total market size in 7MM in comparison to the other major markets, i.e., EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan. According to DelveInsight's analysis, the total cancer pain cases in 2023 for the US were 2.4 million. In 2023, based on the pathophysiology of cancer pain, nociceptive pain accounted for the highest number of cases in the US. Leading cancer pain companies developing emerging therapies, such as InhaleRX, Dogwood Therapeutics, WinSanTor, AlgoTherapeutix, Artelo Biosciences, Asahi Kasei Pharma, and others, are developing novel cancer pain drugs that can be available in the cancer pain market in the coming years. The promising cancer pain therapies in the pipeline include IRX211, HALNEURON (tetrodotoxin), WST-057, ATX01, ART26.12, ART-123, and others. Discover which therapies are expected to grab the major cancer pain market share @ Cancer Pain Market Report Cancer Pain Overview Cancer pain is a common and often debilitating symptom experienced by individuals with cancer, resulting from a variety of causes such as tumor invasion into surrounding tissues, inflammation, nerve compression, or the side effects of treatments like chemotherapy, radiation, and surgery. The nature of cancer pain can vary significantly, it may be acute or chronic, localized or widespread, and described as dull, sharp, burning, or throbbing. Pain not only affects a patient's physical functioning but also takes a toll on emotional well-being, often leading to anxiety, depression, and sleep disturbances. Effective pain management is crucial to maintaining quality of life and supporting overall treatment goals. Cancer Pain Epidemiology Segmentation The cancer pain epidemiology section provides insights into the historical and current cancer pain patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders. The cancer pain market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total Cases of Cancer Pain Etiology-specific Cases of Cancer Pain Incident Cases of Chemotherapy-Induced Peripheral Neuropathy Severity-specific Cases of Cancer Pain Pathophysiology-specific Cases of Cancer Pain Temporal Variation-specific Cases of Cancer Pain Incident Cases of Breakthrough Cancer Pain (BTcP) Cancer Pain Treatment Market Managing chronic cancer-related pain should be personalized, balancing the benefits and drawbacks within the broader context of the patient's overall care goals. When planning pain management, it's important to consider whether disease-modifying treatments are feasible, appropriate, and how they might impact pain. If the pain is localized and caused by tumor pressure or destruction, such as bone lesions, radiotherapy can be very effective. Regardless of whether primary treatments are possible, many patients with active disease-related pain will still require symptom-focused therapies. A thorough pain evaluation is essential to develop a comprehensive, multimodal treatment plan. The first step is to set realistic expectations for the patient, since the cause of the pain affects the likely improvement in pain levels and daily functioning. Patients can be offered various treatment options, including over-the-counter pain relievers, non-opioid prescriptions, procedural interventions, complementary therapies, and systemic opioids. For moderate to severe cancer pain, opioids remain the cornerstone of treatment. Long-term opioid use aims to achieve consistent, meaningful pain relief with manageable side effects, ultimately improving quality of life. Pure μ-opioid receptor agonists are generally preferred for cancer pain, except for drugs like pethidine and dextropropoxyphene, which are discouraged due to their risk of adverse effects. While partial agonists like buprenorphine and mixed-mechanism drugs such as tramadol and tapentadol are options, pure μ-agonists are more commonly used and allow for more flexible dosing. Patients have access to various non-opioid treatment options, which include both medication-based and non-medication approaches. Acetaminophen is often used as a first-choice therapy for patients experiencing mild cancer pain who either do not need opioids or prefer to avoid them. It can also be combined with opioids, and some prescribed medications include both acetaminophen and an opioid in a single tablet for convenience. However, its use in cancer patients is limited due to the risk of liver toxicity, especially in those with liver conditions, and requires careful monitoring for fever in patients with neutropenia. To know more about cancer pain treatment guidelines, visit @ Cancer Pain Management Cancer Pain Pipeline Therapies and Key Companies IRX211: InhaleRX HALNEURON (tetrodotoxin): Dogwood Therapeutics WST-057: WinSanTor ATX01: AlgoTherapeutix ART26.12: Artelo Biosciences ART-123: Asahi Kasei Pharma Discover more about cancer pain drugs in development @ Cancer Pain Clinical Trials Cancer Pain Market Dynamics The cancer pain market dynamics are expected to change in the coming years. The increasing global prevalence of cancer and rising awareness of cancer-associated pain are expected to drive growth in the cancer pain therapeutics market. With no recent drug approvals in this space, pharmaceutical companies have a significant opportunity to penetrate the market, particularly by developing nonopioid-based treatments. As opioids continue to dominate cancer pain management, the anticipated launch of drugs like tetrodotoxin signals a major shift toward novel, nonopioid mechanisms, highlighting the vast potential for innovation in this therapeutic area. Furthermore, potential therapies are being investigated for the treatment of cancer pain, and it is safe to predict that the treatment space will significantly impact the cancer pain market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the cancer pain market in the 7MM. However, several factors may impede the growth of the cancer pain market. Poor assessment of pain, inadequate clinician knowledge, lack of coverage and uneven healthcare reimbursement policies, and the limited effectiveness of standard pain medications such as opioids in cases of refractory pain have all been identified as major barriers to effective cancer pain management, underscoring the need to improve understanding of pain and leverage that knowledge to develop new and more effective treatments. Moreover, cancer pain treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, the cancer pain market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the cancer pain market growth. Cancer Pain Market Report Metrics Details Study Period 2020–2034 Coverage 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan]. Key Cancer Pain Companies InhaleRX, Dogwood Therapeutics, WinSanTor, AlgoTherapeutix, Artelo Biosciences, Asahi Kasei Pharma, and others Key Pipeline Cancer Pain Therapies IRX211, HALNEURON (tetrodotoxin), WST-057, ATX01, ART26.12, ART-123, and others Scope of the Cancer Pain Market Report Therapeutic Assessment: Cancer Pain current marketed and emerging therapies Cancer Pain Market Dynamics: Key Market Forecast Assumptions of Emerging Cancer Pain Drugs and Market Outlook Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, Cancer Pain Market Access and Reimbursement Download the report to understand which factors are driving cancer pain market trends @ Cancer Pain Market Trends Table of Contents 1. Cancer Pain Market Key Insights 2. Cancer Pain Market Report Introduction 3. Cancer Pain Market Overview at a Glance 4. Cancer Pain Market Executive Summary 5. Disease Background and Overview 6. Cancer Pain Treatment and Management 7. Cancer Pain Epidemiology and Patient Population 8. Patient Journey 9. Cancer Pain Marketed Drugs 10. Cancer Pain Emerging Drugs 11. Seven Major Cancer Pain Market Analysis 12. Cancer Pain Market Outlook 13. Potential of Current and Emerging Therapies 14. KOL Views 15. Unmet Needs 16. SWOT Analysis 17. Appendix 18. DelveInsight Capabilities 19. Disclaimer 20. About DelveInsight Related Reports Cancer Pain Epidemiology Forecast Cancer Pain Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the cancer pain epidemiology trends. Advanced Cancer Pain Management Pipeline Advanced Cancer Pain Management Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key advanced cancer pain management companies, including Tetra Bio-Pharma, ZYUS Life Sciences, among others. Advanced Cancer Pain Management Market Advanced Cancer Pain Management Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key advanced cancer pain management companies, including Tetra Bio-Pharma, ZYUS Life Sciences, among others. Cancer Supportive Care Drugs Market Cancer Supportive Care Drugs Market Insights, Competitive Landscape, and Market Forecast – 2032 report deliver an in-depth understanding of the market trends, market drivers, market barriers, and key cancer supportive care drugs companies, including Helsinn Healthcare SA, Merck & Co., Inc., Sanofi, Pfizer Inc., GSK plc, F. Hoffmann-La Roche Ltd., Amgen Inc., Novartis AG, Viatris Inc., Nimbus Therapeutics, Gilead Sciences, Inc., Eli Lilly and Company, Moderna, Inc., AbbVie Inc., Amgen Inc., Regeneron Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Otsuka Holdings Co., Ltd., Affimed GmbH, Bristol-Myers Squibb Company, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact Us Shruti Thakur info@ + Logo: View original content: SOURCE DelveInsight Business Research, LLP Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
42 minutes ago
- Yahoo
Duke Energy Progress proposes new rates to support ongoing efforts to build a smarter energy future for South Carolina customers
Recent investments have strengthened the grid and reduced outages for customers Company last requested a regulatory review of rates in 2022 GREENVILLE, S.C., June 12, 2025 /PRNewswire/ -- Duke Energy Progress today asked South Carolina regulators to perform a public review of the company's current rates. This is the company's first request to review rates since 2022. It comes as the company continues working to increase system diversity and reliability, enhance the customer experience and meet future energy demands. Duke Energy Progress serves about 177,000 customers primarily in central and northeastern South Carolina. By the numbers: The company's application in front of the Public Service Commission of South Carolina (PSCSC) requests an overall revenue increase of $74.8 million, which represents a 12.1% increase over current revenues. If approved, monthly electric bills for typical residential customers using 1,000 kilowatt-hours per month would increase $21.66 a month – from $144.85 per month to $166.51 – effective Feb. 1, 2026. Commercial customers will see an average increase of 12.8% and industrial customers will see an average increase of around 3.6%. The amount of increase per customer class can vary based upon how much more additional revenue is needed to ensure that the class is covering the cost to serve them. Why it matters: Duke Energy is committed to meeting customers' increasingly higher expectations around reliability, responsiveness, affordability and value. This proposal reflects the investments we have made to strengthen the grid, improve storm readiness, maintain and enhance our generating fleet and serve a growing customer base. It also reflects how the company is doing that work: with discipline, with a focus on operational excellence, and with a thoughtful approach to how and when we seek rate adjustments. Investments in action: The company's grid investments have positioned it well for storm response. For example, as Hurricane Helene made its way across the Carolinas, grid improvements were already helping to combat power outages from the storm. Smart, self-healing technology installed across the Duke Energy Progress service territory helped to automatically restore more than 10,000 customer outages and saved more than 28,000 hours of total outage time, showing the value of the self-healing programs. Our view: "We know families and businesses are juggling a lot and we do not take a request to increase rates lightly but being upfront and timely with our request is the right thing to do and in the best interest of our customers." – Tim Pearson, Duke Energy's South Carolina president More info: Details on the company's proposal, the rate review process and the variety of assistance programs and billing options offered by the company can be found here. Duke Energy ProgressDuke Energy Progress, a subsidiary of Duke Energy, owns 13,800 megawatts of energy capacity, supplying electricity to 1.8 million residential, commercial and industrial customers across a 28,000-square-mile service area in North Carolina and South Carolina. Duke EnergyDuke Energy (NYSE: DUK), a Fortune 150 company headquartered in Charlotte, N.C., is one of America's largest energy holding companies. The company's electric utilities serve 8.6 million customers in North Carolina, South Carolina, Florida, Indiana, Ohio and Kentucky, and collectively own 55,100 megawatts of energy capacity. Its natural gas utilities serve 1.7 million customers in North Carolina, South Carolina, Tennessee, Ohio and Kentucky. Duke Energy is executing an ambitious energy transition, keeping customer reliability and value at the forefront as it builds a smarter energy future. The company is investing in major electric grid upgrades and cleaner generation, including natural gas, nuclear, renewables and energy storage. More information is available at and the Duke Energy News Center. Follow Duke Energy on X, LinkedIn, Instagram and Facebook, and visit illumination for stories about the people and innovations powering our energy transition. Contact: Ryan Mosier 24-Hour: 800.559.3853 View original content to download multimedia: SOURCE Duke Energy Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Eisenhower Fellowships names 2025 Southeast Asia Fellows
Fifteen ascendant leaders from ASEAN nations to travel to U.S. this fall PHILADELPHIA, June 12, 2025 /PRNewswire/ -- Eisenhower Fellowships (EF) has selected 15 exceptional mid-career leaders from diverse professional fields for its prestigious 2025 Southeast Asia Program, nearly six weeks of intensive travel across the United States to meet with experts in their respective professions. The ascendant leaders from six Southeast Asian countries will embark on a transformative, nearly six-week fellowship journey across the U.S. in October designed to foster dialogue and cross-cultural exchange. They will engage with international peers and American thought leaders to explore new ideas, forge collaborative partnerships and give shape to projects of impact they will implement upon their return home. The Fellows selected for the 2025 Southeast Asia Program are from Indonesia, Malaysia, the Philippines, Singapore, Thailand and Vietnam. These dynamic leaders drive change in fields ranging from public policy and artificial intelligence to music, medicine and climate innovation. They bring with them to the U.S. an impressive array of impactful initiatives, including a digital health platform for dementia caregivers, an AI ethics curriculum for public servants, a deep tech innovation hub and plans for a new major international arts festival in Hanoi. The Southeast Asia Fellows are developing pioneering approaches to advance their work in their individual countries and across their region. Each embodies EF's mission to promote peace, prosperity, and justice through international understanding and collaboration. They will apply what they learn on fellowship to better their societies after they return home. "Fifty years after the end of the war in Vietnam, we are proud to welcome to the United States exceptional leaders from that former enemy and other friendly nations in the region for fruitful people-to-people exchanges that will strengthen ties between future leaders of our countries," said EF's chairman, former U.S. Secretary of Defense Dr. Robert M. Gates. The 2025 Eisenhower Fellows from Southeast Asia are: Yoga Adiwinarto, Director of Business Development, KALISTA (Indonesia) Vịnh Cao, Artist, Music Producer, and Composer, Space Speakers Label (Vietnam) Rena Dharmawan, Consultant Surgeon, National Cancer Centre (Singapore) Matthew Durai, Founder and Executive Producer, ZAG Studios (Malaysia) Erika Fille Legara, Managing Director, Center for AI Research (Philippines) Jane Lim, Deputy Secretary of Trade and International Economic Relations, Ministry of Trade and Industry (Singapore) Pak Shun Ng, Group Chief, Policy and Strategy; Group Chief, Plans and Transformation, Ministry of Defense (Singapore) Tien Nguyen, Founding Partner, Earth Venture Capital (Vietnam) Supachai Parchariyanon, Chief Executive Officer and Co-Founder, RISE (Thailand) Saiyai Sakawee, Head of Consumer Communications, SEA and South Asia Frontier Markets, Google (Thailand) Santitarn Sathirathai, Member, Monetary Policy Committee, Bank of Thailand (Thailand) Trang Trinh, Concert Pianist and Arts Leader, All Bodies Dance (Vietnam) Cindy Vuu, Chief Executive Officer, Binh Tien Consumer Goods Manufacturing LC (Vietnam) Parit Wacharasindhu, Member of Parliament, House of Representatives (Thailand) Steven Wongsoredjo, Co-Founder and Chief Executive Officer, SuperApp (Indonesia) Founded in 1953 and named for President Dwight D. Eisenhower, EF connects leaders from diverse fields and countries to exchange ideas, foster collaboration and promote international understanding. With a network of nearly 1,900 active Fellows in scores of nations, EF inspires, connects and empowers leaders to take on some of the world's most urgent challenges with creativity, determination and purpose. For more information contact:Erin Hillman, Vice President of Programs and Operationsehillman@ View original content to download multimedia: SOURCE Eisenhower Fellowships Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
